Prosecution Insights
Last updated: July 17, 2026
Application No. 18/260,908

Treatment of Neuropathic Sensitization Disorders

Non-Final OA §101§102§112
Filed
Jul 10, 2023
Priority
Jan 11, 2021 — provisional 63/205,848 +1 more
Examiner
WARD, PAUL V
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Iview Therapeutics Inc.
OA Round
1 (Non-Final)
83%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
72%
With Interview

Examiner Intelligence

Grants 83% — above average
83%
Career Allowance Rate
1408 granted / 1692 resolved
+23.2% vs TC avg
Minimal -12% lift
Without
With
+-11.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
36 currently pending
Career history
1716
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
29.6%
-10.4% vs TC avg
§102
8.5%
-31.5% vs TC avg
§112
42.9%
+2.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1692 resolved cases

Office Action

§101 §102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION STATUS OF THE CLAIMS: Claims 1-20 are pending in this application. Election/Restrictions Applicant’s election of species in the reply filed on December 18, 2025 is acknowledged. All claims were examined in its entirety. Claim Rejections - 35 USC § 101 & 35 USC § 112, 1st paragraph 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 19-20 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by either an asserted utility or a well established utility. The claims are “Use” claim, and use claims are directed to non-statutory subject matter. Claim Rejections - 35 USC § 112, 1st paragraph The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 19-20 are also rejected under 35 U.S.C. 112(a) or pre-AIA 35 U.S.C. 112, first paragraph. Specifically, because the claimed invention is not supported by either an asserted utility or a well-established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-3, 13-15, and 19-20 are rejected under 35 U.S.C. 102 as being anticipated by Wei et al. US Pub. 2015/016,924). Applicant claims the following method for treating neuropathic ocular pain: PNG media_image1.png 238 652 media_image1.png Greyscale PNG media_image2.png 780 652 media_image2.png Greyscale This reference discloses Applicant’s methods on page 26, lines 1-10, paragraphs [0046]-[0047], [0050], [0178], and [0255]. (See Abstract and entire document). The methods read on the instant claim. Since this reference teaches the exact methods, Applicant’s claims are anticipated, and thus, rejected under 35 U.S.C. 102. Regarding claim 2, this reference discloses Applicant’s method in, paragraphs [0035], [0041]-[0042], and [0255], and regarding claim 3, this reference discloses Applicant’s method in paragraph [0255]. Regarding claims 13-15, this reference discloses Applicant’s methods on page 26, paragraphs [0258] left column, page 26, lines 1-10, paragraphs [0046]-[0047], [0050], [0178], and [0255]. (See Abstract and entire document). Additionally, in paragraphs [0035], [0041]-[0042], and [0255], this reference disclose the method of Applicant’s claim 14. Further, this reference discloses Applicant’s method of claim 15 in paragraphs on page 27, lines 16-17. Regarding claims 19-20, this reference discloses Applicant’s methods on page 26, paragraphs [0258] left column, page 26, lines 1-10, paragraphs [0046]-[0047], [0050], [0178], and [0255], and on page 27, lines 16-17. Since this reference teaches the exact methods, Applicant’s claims are anticipated, and thus, rejected under 35 U.S.C. 102. Claims 4-12 and 16-18 are rejected for being dependent on a rejected claim. Conclusion Claims 1-20 are pending. Claims 1-20 are rejected. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to PAUL V WARD whose telephone number is (571)272-2909. The examiner can normally be reached M-F 9am to 5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James Alstrum-Acevedo can be reached at 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PAUL V WARD/ Primary Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Jul 10, 2023
Application Filed
Mar 27, 2026
Non-Final Rejection (signed) — §101, §102, §112
May 12, 2026
Non-Final Rejection mailed — §101, §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12678384
SANITIZING COMPOSITIONS CONTAINING IONIC LIQUID
3y 6m to grant Granted Jul 14, 2026
Patent 12679810
METHOD FOR THE PREPARATION OF SULFINPYRAZONE
3y 3m to grant Granted Jul 14, 2026
Patent 12673057
RIPK2 INHIBITION FOR THE TREATMENT OF CANCER
3y 9m to grant Granted Jul 07, 2026
Patent 12661432
MULTIFUNCTIONAL, HYDROGEL HYBRID MATERIAL, THE METHOD OF ITS PREPARATION AND THE USE IN THE TREATMENT OF BONE LOSSES
3y 3m to grant Granted Jun 23, 2026
Patent 12655141
INHIBITORS OF NOTCH SIGNALING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS
4y 8m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
83%
Grant Probability
72%
With Interview (-11.5%)
2y 4m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1692 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month